Drug Safety Symposium – Excellence in pharmaceutical

India Chapter - June, 2025

Dubai Chapter - Feb 12th - 13th, 2025

About

In today's dynamic healthcare landscape, the burgeoning trend of prioritizing patient centricity and drug safety reflects a fundamental shift towards a more holistic and proactive approach to healthcare delivery and pharmaceutical innovation.

We proudly present Drug Safety Symposium – Dubai & India Chapter, with a focus on enhancing drug safety practices and fostering collaboration among industry stakeholders, our symposium promises to be an enriching experience for all participants.

A Uniquely Engaging Event

What distinguishes the Drug Safety Symposium is our distinctive approach. We blend insightful knowledge sharing with interactive workshops and networking sessions, all infused with a spirit of camaraderie and enjoyment. It's not merely an event; it's an enriching experience that equips you to make informed decisions and contribute to elevating the standards of drug safety and quality.

Join us at the Drug Safety Symposium to be part of a dynamic exchange of knowledge and insights shaping the future of drug safety in India and beyond.

Why Attend

Who Should Attend

Pharmacovigilance professionals
Regulatory affairs specialists

  • Navigating Complex Regulatory Frameworks
  • Good Pharmacovigilance Practices (GVP): An Overview

Quality assurance professionals

  • FDA and EMA Regulations: A Comparative Analysis
  • Efficient Adverse Event Reporting

Pharmaceutical industry leaders

  • Innovations in Pharmacovigilance: Harnessing Data and Technology
  • Artificial Intelligence and Machine Learning in Pharmacovigilance
  • Digital Health and Real-World Evidence

Medical professionals involved in drug safety

  • Clinical Trials and PV Intervention
  • Ensuring Data Integrity and Quality Assurance in PV Operations
  • Drug Labelling and Communication

Academics and researchers in pharmacovigilance

  • The Role of Quality Assurance in Drug Safety
  • Implementing Quality Control Measures for Drug Manufacturing

Representatives from regulatory authorities

  • Clinical Trials and PV Intervention
  • Ensuring Data Integrity and Quality Assurance in PV Operations
  • Drug Labelling and Communication

Scroll to Top